The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

被引：99

作者：

Bahrami, Afsane ^{[1
,2
]}

Khazaei, Majid ^{[3
]}

Shahidsales, Soodabeh ^{[4
]}

Hassanian, Seyed Mahdi ^{[5
,6
]}

Hasanzadeh, Malihe ^{[7
]}

Maftouh, Mina ^{[5
]}

Ferns, Gordon A. ^{[8
]}

Avan, Amir ^{[5
]}

机构：

[1] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran

[2] Mashhad Univ Med Sci, Student Res Comm, Fac Med, Mashhad, Iran

[3] Mashhad Univ Med Sci, Dept Physiol, Fac Med, Mashhad, Iran

[4] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran

[5] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran

[7] Mashhad Univ Med Sci, Dept Gynecol Oncol, Woman Hlth Res Ctr, Mashhad, Iran

[8] Brighton & Sussex Med Sch, Div Med Educ, Brighton BN1 9PH, Sussex, England

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2018年 / 119卷 / 01期

关键词：

PI3K/Akt/mTOR INHIBITORS; EVEROLIMUS; BREAST CANCER; PHASE IB; WEEKLY PACLITAXEL; MAMMALIAN TARGET; PIK3CA MUTATIONS; AKT-INHIBITOR; TRASTUZUMAB; MTOR; EVEROLIMUS; RESISTANCE; PATHWAY;

D O I：

10.1002/jcb.26136

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213-222, 2018. (c) 2017 Wiley Periodicals, Inc.

引用

页码：213 / 222

页数：10

共 59 条

[1]

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab [J].